Toby Goldblatt

Great to catch up with Lee Maw, Subroto Mukherjee and Bradley Quinn on how companies in the life sciences industry are driving innovation in with AI. Here’s a few of the key points that we covered; 👩🏽‍💻Data quality is paramount. Without accurate and reliable data, AI models cannot deliver meaningful or impactful results. ⚖️ Ethics matter. In all industries, particularly life sciences, prioritising patient safety, privacy, and fairness in AI algorithms and decision-making is crucial. 📜 Regulation is evolving. The regulatory landscape will play a critical role in determining how AI can be responsibly and effectively deployed. Life sciences is truly a unique and exciting space for AI, and I’m looking forward to seeing how progress in this area changes the way we live. 🚀 #AI #LifeSciences #DataQuality #AIethics #AIRegulation https://hubs.la/Q02N09jK0

7

One of the hugely positive impacts that AI is expected to have on society in the coming years, is in the healthcare sector. And that is why I was delighted to attend the official opening of the SAS Advanced Analytics Hub at The Maxwell Centre, University of Cambridge last week. The partnership aims to accelerate healthcare innovation through enhanced access to advanced analytics. It will embed SAS experts and SAS® Viya® data and AI platform capabilities into the University environment, enabling targeted collaboration to “find the quickest way from a billion points of data to a point of view”. The hub will have capacity to recruit and support several high-quality, high-impact academic research projects and promising early-stage startups in the health-tech space, providing their innovative ideas with extra momentum. We believe this combination of expertise can tackle some of the world’s biggest challenges, which is why it’s such an exciting project. We’ve already had a taste of what can be achieved. A University of Cambridge-led project on kidney transplants, PITHIA, developed an AI-based decision support approach using SAS’ analytics platform. It is being used to automate the process of scoring biopsies for kidneys to better identify those organs that can be used for transplantation. This has the potential to save lives and transform the quality of life for more than 100 people each year who would otherwise require dialysis, as well as saving the NHS millions of pounds annually. Professor Nigel Peake (Chair of the Maxwell Centre) and Gail Stephens (Vice President Health and Life Sciences at SAS) formally opened the analytics hub and it was a great pleasure to be joined by distinguished individuals involved in scientific research, as well as SAS colleagues. And a massive thank you to those that made this partnership possible, including Dr Alexander Samoshkin, from the Office for Translational Research at the University, and Dr Agnieszka Iwasiewicz-Wabnig FRSA, Maxwell Centre Director. I would like to thank all those involved in the organisation of the event including Monica Lucena, Katy Cordingley, Mayra Pedraza, Anne Okwuzi and special thanks to the SAS team who worked so hard to secure this collaboration: Geoffrey Taylor, Glyn Townsend, Mark Lambrecht, Stephen Kearney, Anu Sharma Pereira, David Shannon, Peter Andersen and Nicky Furlong. #CambridgeUniversity #Partnership #DataForGood #Analytics #AI #healthcare

141

10 Comments

I’m at HETT today, and had the opportunity to attend a really insightful session on Process Mining hosted by Tremaine Richard-Noel that highlighted the transformative potential of harnessing existing data in healthcare. Judith May showcased how presenting existing data in more valuable ways can uncover variations in patient experiences, directly pinpointing areas ripe for efficiency improvements. It's remarkable how these insights can lead to more targeted and effective interventions. Similarly Santosh Kumar discussed the common disconnect between theoretically well-designed processes and their practical execution. Through process mining, they quantified how a significant factor in ED wait times is the wait for diagnostic tests. By focusing on reducing repeat tests and addressing staff unavailability, issues they were aware of but hadn't fully quantified, they could see the broader impact on the entire system. Another compelling example was how University Hospitals Dorset NHS Foundation Trust found appointment reminders sent at 10 and 3 days caused peaks in patient cancellations, making it challenging to fill slots on short notice. They are now trialing a new approach to reduce last-minute cancellations. These real-world applications of process mining perfectly align with our Delivering Value through Digital approach, demonstrating how data-driven strategies can identify where interventions will deliver the most value, enhancing efficiency and improving patient outcomes. The opportunities in this space are immense, and I'm excited to see how we can continue to leverage these insights to drive meaningful change in healthcare. #HETT24 #Channel3Consulting #digital

9

1 Comment

Explore the challenges faced by the public healthcare industry today and find out how digital transformation can foster a more efficient, “healthier” ecosystem in my Credera colleague Anna Bedford's latest blog.

4

The UK Genomics Spotlight 2024 highlights the remarkable achievements and evolving potential of the UK as a global leader in genomics, showcasing its legacy from the groundbreaking 100,000 Genomes Project to today’s pioneering NHS Genomic Medicine Service. The UK’s ecosystem, driven by world-class universities, national initiatives and transformative digital infrastructure, has firmly established genomics as a core part of healthcare, with innovative strides across rare diseases, cancer, precision medicine, and more. The vision for the future is clear: the UK will continue to harness genomic data to advance early diagnosis, personalised treatment, and ultimately, improved patient outcomes. At Healthcare Innovation Consortium (HIC), we are proud to support this ambitious national goal. Our deep-rooted expertise spans both local and national digital health initiatives, bringing together knowledge from a variety of UK health systems and sectors. We understand the complexity of integrating genomics into routine clinical care - a challenge that requires not only advanced digital infrastructure but also robust data interoperability, governance and ethical considerations. By leveraging our hands-on experience with NHS trusts and our extensive partnerships across academia and industry, we are able to deliver solutions that address these complex needs effectively and sustainably. As part of the UK’s journey to a genomics-first future, HIC is committed to advancing digital innovation that enables the seamless integration of genomic data into healthcare workflows. We specialise in creating scalable, interoperable systems that support clinicians, researchers and policy-makers alike. Our work in this transformative field allows us to contribute to something uniquely impactful - helping to bring genomic insights into day-to-day patient care. This work is complex, but it’s precisely the kind of challenge that drives us. HIC is honoured to be at the forefront of digital health innovation, empowering the NHS and the life sciences sector to realise their full potential in genomics and beyond. As we look ahead, we ask some key questions that will shape the future of genomics in healthcare: How can we best align genomic data with existing health records to ensure a seamless experience for patients and clinicians? What steps must be taken to enhance data privacy and ethical frameworks as we advance genomics on a national scale? How can we foster stronger collaborations between the NHS, industry and academic partners to accelerate innovation? Thoughts welcomed! We look forward to supporting the NHS and industry in the years to come, driving forward this shared ambition to deliver a future where genomics transforms lives across the UK. #Genomics #DigitalHealth #Innovation #NHS #HealthcareTransformation #PrecisionMedicine #FutureOfHealth

15

⏩️ excellent review! maybe we need to reneame it “from raw data to evidence (#RWE)” in our ecosystem? 🔂 maybe we need to revisit the value of such data for public health in light of financial implications described in other settings? 🆓 nothing is for free but maybe better utilizing the abundance of already available data could dramatically reduce costs - rendering healthcare delivery as well as R&D much more efficient! 🔀 Full disclosure: no affiliation!

8

'NHS cancer services and systems— ten pressure points a UK cancer control plan needs to address' was published this week in The Lancet #Oncology and includes: 3️⃣ “Little use of #PROMs & #PREMs to evaluate psychological & physical morbidity of #cancer care 👉 Invest in routine collection of PROMs & PREMs to understand unmet burden of toxicities following treatment & benchmark quality” 5️⃣ “Despite huge investment in R&D, up to 50% of patients are not receiving evidence-based care 👉 Monitoring of care & #outcomes through national audits & National Disease Registration Service is essential & should be expanded to complex tumours & integrate PROMs” https://lnkd.in/djtZnNQJ

9

How can we strengthen the ROI of incorporating digital biomarkers in drug development trials and accelerate its adoption… looking forward to hearing the sessions today and sharing the insights! #DigitalBiomarkersSummit #medidata #clinicalinnovation

13

The UK's delicate industrial strategy balancing act: our service industry must embrace GenAI, but the risk is that we hand our future to US BigTech. My article in Bright Blue's new collection of essays on the impact of Generative AI, alongside such luminaries as Kenneth Cukier Rose Luckin Gerard Grech Tom Watson. "It is easy to be cynical about endless promises surrounding the transformative potential of AI. However, even if the current break-neck pace of technological development were to slow down, we are already seeing the first stirrings of a productivity revolution, especially in the services industry. This matters because the UK is the second-biggest exporter of services in the world, and, at present, we face a conundrum. If we do not embrace the AI opportunity, then we risk falling behind and losing our competitive edge. But, if we do fully embrace AI, we risk handing the keys to our economy over to the US tech giants on whose AI platforms our technological future depends." Let's hope that the next Government has the bandwidth and vision to focus on both aspects of this challenge. Do check out pages 38-39 (as well as all the other great articles obviously) for the Best Practice AI view on this. With thanks to Sarah Kuszynski and Ryan Shorthouse. https://lnkd.in/g8CJtAkJ

26

4 Comments

AI tax - interesting concept Benyamin Deldar.

18

1 Comment

Please reach out if you'd like to learn more about how PeakData uncovers hidden HCPs that are influential or active in disease management for its clients!

6

❓How can investing in life sciences make both the UK economy and society healthier? Our Life Sciences Future50 report illustrates a sample of companies that are pioneering innovation to accelerate the pace of research for better patient outcomes. Is the UK on track to realise our ambition of becoming a leading hub in #LifeSciences? 📑Explore the report to find out the critical success factors and the transformative impact these companies are making: #LifeSciences #BioTech #DigitalHealth#F50 https://bit.ly/4ekCdoR

8

1 Comment

For all the health people in my network, please fill in this survey. Explain to NHS England that this is a terrible idea that will create further barriers to innovation when we need it most. The UK can be a powerhouse in medtech innovation but not like this. Empower the frontline to seek innovations that solve the real world problems they face. Award contracts for real implementations not pilots and trials or schemes. Listen to the recent report from The Health Foundation and send a signal that centralised pathways are not a solution https://lnkd.in/eHfgNGXK

10

4 Comments

As industry makes great strides in working 'with’ patients, not only ‘for’ patients, wider adoption of impact measurement, such as through this co-created framework, will demonstrably improve provision and access to treatments with effects that really matter to patients. As such, the authors call on colleagues across the pharmaceutical industry to join us in applying impact measurement to measure, publish, and communicate the value of #patientengagement and its impact. #patient #patientcentricity #ispor #value #medicalaffairs #heor #pharma #biopharma #realworldoutcomes #outcomesresearch #patientvoice #outcomesresearch #healtheconomics #marketaccess #drugdevelopment ISPOR—The Professional Society for Health Economics and Outcomes Research

11

"Value and access teams are responsible for the clinical, economic, and humanistic evidence for submission to HTA authorities, payers, hospitals, and health systems. These stakeholders use the evidence to determine the added benefit over the current standard of care, support price negotiations, and inform coverage and reimbursement decisions. Value and access teams also seek scientific advice from HTA authorities and confirm that the clinical and modeling studies meet the methodological requirements for submission to HTA authorities." (Boston Consulting Group; "The Future of Integrated Evidence Planning in Biopharma")

1

Jordan Sollof, reporter at Digital Health News, is joined by Lloyd Price and Mohammad Al-Ubaydli to talk about procurement and why the NHS is so difficult to sell to. https://lnkd.in/eaW4F2hC From their own experience, Price, a healthtech founder, mergers and acquisitions advisor and non-executive director for various digital health companies, and Al-Ubaydli, founder and chief executive of digital health social enterprise, Patients Know Best, shine a light on the main issues that can make selling to the NHS a challenge. The pair discuss success stories of startups which have successfully sold to the NHS, before assessing whether companies and suppliers need to take more care in ensuring they are pitching the right solution to the right organisation. They give their views on whether the NHS procurement process has become overcomplicated, a point raised in a session at Rewired 2024, and speculate whether the forthcoming Procurement Act (which was originally due to come into force in October 2024, but has been delayed until February 2025) will solve some issues and make it easier for those selling in the health technology sector. Finally, the guests predict what they anticipate will happen in the coming months and years, including whether the NHS will become a simpler system as a whole to sell to or if we will still be having the same conversation about difficulties selling in a few years’ time. Guests: Lloyd Price, health tech founder, mergers and acquisitions advisor and non-executive director for various digital health companies Mohammad Al-Ubaydli, founder and chief executive of Patients Know Best #HealthTech #DigitalHealth #HealthIT #NelsonAdvisors #Mergers #Acquisitions #Growth #Strategy #Partnerships #VentureCapital #PrivateEquity 

15

1 Comment

So good to see this. #dataforgood. We have toiled hard for almost 5 years because we know data can solve many societal issues, especially when the right sources can be linked. We have engineered our platform to protect the consumer from being reidentified, while making data linkable and contained analytics possible so that we can solve financial inclusion, reduce fraud and even hopefully cure cancer. Over regulating is often as harmful as under regulating.

16

So good to see this. #dataforgood. We have toiled hard for almost 5 years because we know data can solve many societal issues, especially when the right sources can be linked. We have engineered our platform to protect the consumer from being reidentified, while making data linkable and contained analytics possible so that we can solve financial inclusion, reduce fraud and even hopefully cure cancer. Over regulating is often as harmful as under regulating.

4

"After the Consultants Have Left the Building" - our blog explores what explores the difference between a consultant’s report, and true consultancy support. Learn how to truly leverage insights created through experience for your market strategy and why a bespoke consulting approach can be more beneficial. 🔗 https://lnkd.in/eFT93BW8 #BusinessConsulting #MarketStrategy #MedicalInnovation #Medtech #MedicalDevices #HealthTech #DigitalHealth #HealthCareInnovation #MedDevice #NHSMarketAccess

4